

Hypomorphic mutation in SFTPB leads to adult pulmonary fibrosis

Tifenn Desroziers, Grégoire Prévot, Aurore Coulomb, Valérie Nau, Florence Dastot-Le Moal, Philippe Duquesnoy, Mélanie Héry, Aurélie Le Borgne, Serge Amselem, Marie Legendre, et al.

► To cite this version:

Tifenn Desroziers, Grégoire Prévot, Aurore Coulomb, Valérie Nau, Florence Dastot-Le Moal, et al.. Hypomorphic mutation in SFTPB leads to adult pulmonary fibrosis. European Respiratory Society, Sep 2023, Milan (Italie), Italy. inserm-04208358

HAL Id: inserm-04208358 https://inserm.hal.science/inserm-04208358v1

Submitted on 15 Sep 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Hypomorphic mutation in SFTPB leads to adult pulmonary fibrosis


Introduction -

- interstitial lung diseases (ILD) in **newborns** and exceptional survival in young children.
- The aim of the study was to investigate **the pathogenicity effect** of the variation **c.582G>A p.(Gln194=)**

Results

Case presentation

- The proband, homozygous for the variation (Fig.1A), presented a fibrosing ILD at 34 years. His thoracic CT-scan showed ground glass opacities and fibrosis. He received a bi-pulmonary transplantation at 51 years (Fig.1B).
- **Proband's son, also homozygous for the variation (Fig.1A) presented** alveolo-interstitial opacities and mild alveolar hemorrhage at 10 months. His thoracic CT-scan at 16 years showed mild ground glass opacities and mild ILD at 22 years (Fig.1B).



Inserm

Figure 1: (A) Genealogical tree of the described family. The genotypes are provided with the reference nucleotide in green and the pathogenic variant in red. (B) The CT-scan of the proband at 51 years (left) and his son at 16 years (right)

Conclusion and perspectives


- explain the long-term survival with fibrosing ILD in the two related adults.




Surfactant protein (SP)-B deficiency due to bi-allelic pathogenic variation has been associated with fatal forms of

We herein report for the first time two related adults with pulmonary fibrosis due to a homozygous SFTPB variation.

Impact of the variation c.582G>A p.(Gln194=)





The pathogenic variation c.582G>A p.(Gln194=) affected drastically splicing and leading to a residual SP-B expression, could


These findings lead to considered SFTPB variants in atypical presentations of ILD particularly in a familial context.





Tifenn Desroziers¹, Grégoire Prévot², Aurore Coulomb³, Valérie Nau⁴, Florence Dastot-Le Moal⁴, Philippe Duquesnoy¹, Mélanie Héry¹, Aurélie Le Borgne², Serge Amselem^{1,4}, Marie Legendre^{1,4,*}, Nadia Nathan^{1,5,*}

(1) Laboratory of childhood genetic diseases, Armand Trousseau Hospital, Sorbonne University and Inserm UMR_S933, Paris, France (2)Respiratory Medicine, Toulouse University Hospital, Toulouse, France. (3)Sorbonne University, Assistance Publique – Hôpitaux de Paris, Pathology department, Armand Trousseau Hospital, Paris, France. (4) Molecular Genetics unit, Laboratory of Childhood genetic diseases, Armand Trousseau Hospital, Sorbonne University, Assistance Publique – Hôpitaux de Paris and Inserm UMS_S933, Paris, France. (5) Pediatric pulmonology department, Reference center for rare lung diseases RespiRare, Laboratory of childhood genetic diseases Inserm UMR S933, Armand Trousseau Hospital, Sorbonne University and APHP, Paris, France



In vitro transcription analysis of the variation c.582G>A : overexpression of SFTPB genomic constructs spanning exon 4 to 6 (NM_000542.5), WT or mutated in A549 cells. Analysis by electrophoresis and Sanger sequencing of the

Ex vivo studies : Haematoxylin & eosin (HE) stainings and immunostaining targeting SP-B and SP-C assessed on

eosin (HE) staining, SP-B and SP-C staining (magnification x20 and x40).



Desroziers et al. Eur J Hum Genet 2023 tifenn.desroziers-louedec@inserm.fr, nadia.nathan@aphp.fr